© Reuters. FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
COPENHAGEN (Reuters) – Denmark’s government on Monday asked the country’s health authorities to reconsider a decision to exclude Johnson & Johnson (NYSE:)’s and AstraZeneca’s (L:) COVID-19 shots from its vaccination programme.
The move was prompted by a two-week delay in the Danish vaccination programme to September due to delivery of fewer Moderna (NASDAQ:) and CureVac vaccines than expected, Health Minister Magnus Heunicke said.
Denmark excluded the J&J and AstraZeneca vaccines over a potential link to a rare but serious form of blood clot.
“We are now further into the epidemic, and the vaccines from Johnson & Johnson and AstraZeneca have now been in use in Europe for some time, Heunicke said.
“There is a larger data base worldwide to assess the effect and side effects of the vaccines,” he said.
The health authority found in early May that the benefits of using the COVID-19 vaccines did not outweigh the risk of causing the possible adverse effect in those who receive the vaccine.
Excluding the J&J vaccine, which accounts for around a third of Denmark’s total contracted supplies of COVID-19 shots, delayed the country’s vaccination calendar by up to four weeks, the health authority said.
Denmark had vaccinated 21% of its population as of Monday.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.